The Canadian Agency for Drugs and Technology in Health (CADTH) has issued a call for patient input regarding GSK’s Breo Ellipta fluticasone furoate/vilanterol DPI for the treatment of asthma. According to the announcement, the agency has received notice of a pending submission and is seeking input from patient groups for purposes of a Common Drug Review.
According to the agency’s website, “Once Health Canada has approved a drug for use in Canada, the country’s public drug plans must decide if the drug will be eligible for public reimbursement. The CADTH Common Drug Review (CDR) plays an important role in their decision-making processes.”
Reviews may take place prior to approval and may be for new drugs or drugs approved for new indications. Breo Ellipta was approved in Canada for the treatment of COPD in July 2013.
The patient input period is open from June 30, 2015 to August 20, 2015.
Read the CADTH call for patient input.
